Literature DB >> 19571029

Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts.

Ana Espinel-Ingroff1, E Canton, J Peman, M G Rinaldi, A W Fothergill.   

Abstract

We evaluated the performance of the 24-h broth microdilution voriconazole MIC by obtaining MICs for 2,162 clinical isolates of Candida spp. and other yeasts; the 24-h results were compared to 48-h reference MICs to assess essential, as well as categorical, agreement. Although the overall essential agreement was 88.6%, it ranged from 96.4 to 100% for 6 of the 11 species or groups of yeasts tested. The overall categorical agreement was 93.2%, and it was above 90% for eight species. However, unacceptable percentages of very major errors (false susceptibility) were observed for Candida albicans (2.7%), C. glabrata (4.1%), C. tropicalis (9.7%), and other less common yeast species (9.8%). Since it is essential to identify potentially resistant isolates and breakpoints are based on 48-h MICs, it appears that the 24-h MIC is not as clinically useful as the 48-h reference MIC. However, further characterization of these falsely susceptible MICs for three of the four common Candida spp. is needed to understand whether these errors are due to trailing misinterpretation or if the 48-h incubation is required to detect voriconazole resistance. Either in vivo versus in vitro correlations or the determination of resistance mechanisms should be investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571029      PMCID: PMC2738097          DOI: 10.1128/JCM.00654-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

2.  Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.

Authors:  A Espinel-Ingroff; E Canton; D Gibbs; A Wang
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

3.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

4.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

5.  Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; A Fothergill; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; M G Rinaldi; R Barnes; B Hu; A V Veselov; N Tiraboschi; E Nagy; D L Gibbs
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

7.  The trailing end point phenotype in antifungal susceptibility testing is pH dependent.

Authors:  K A Marr; T R Rustad; J H Rex; T C White
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

8.  Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.

Authors:  Shelley S Magill; Christine Shields; Cynthia L Sears; Michael Choti; William G Merz
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

9.  Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

10.  Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948

View more
  14 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method.

Authors:  Shawn R Lockhart; Carol B Bolden; Naureen Iqbal; Randall J Kuykendall
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

3.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

4.  Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia.

Authors:  Jesús Guinea; Sandra Recio; Pilar Escribano; Marta Torres-Narbona; Teresa Peláez; Carlos Sánchez-Carrillo; Marta Rodríguez-Créixems; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

5.  Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2010-12-15       Impact factor: 5.948

6.  Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study.

Authors:  Elisa Borghi; Roberta Iatta; Rita Sciota; Caterina Biassoni; Teresa Cuna; Maria Teresa Montagna; Giulia Morace
Journal:  J Clin Microbiol       Date:  2010-07-14       Impact factor: 5.948

7.  A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans.

Authors:  Arome Solomon Odiba; Olanrewaju Ayodeji Durojaye; Ifeoma Maureen Ezeonu; Anthony Christian Mgbeahuruike; Bennett Chima Nwanguma
Journal:  Infect Drug Resist       Date:  2022-06-17       Impact factor: 4.177

8.  A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans.

Authors:  Jennifer L A Rabjohns; Yoon-Dong Park; Jean Dehdashti; Christina Henderson; Adrian Zelazny; Steven J Metallo; Wei Zheng; Peter R Williamson
Journal:  J Biomol Screen       Date:  2013-07-29

9.  Photodynamic antimicrobial chemotherapy (PACT) using toluidine blue inhibits both growth and biofilm formation by Candida krusei.

Authors:  Bruna Graziele Marques da Silva; Moisés Lopes Carvalho; Isabela Bueno Rosseti; Stella Zamuner; Maricilia Silva Costa
Journal:  Lasers Med Sci       Date:  2018-01-13       Impact factor: 3.161

10.  Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients.

Authors:  Giulia Morace; Elisa Borghi; Roberta Iatta; Gerardino Amato; Stefano Andreoni; Gioconda Brigante; Claudio Farina; Giuliana Lo Cascio; Gianluigi Lombardi; Ester Manso; Michele Mussap; Patrizia Pecile; Roberto Rigoli; Elisabetta Tangorra; Maria Valmarin; Maria Teresa Montagna
Journal:  BMC Infect Dis       Date:  2011-05-17       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.